Deutsche Bank AG Purchases Shares of 651,784 AxoGen, Inc. $AXGN

Deutsche Bank AG purchased a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 651,784 shares of the medical equipment provider’s stock, valued at approximately $30,106,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. MCF Advisors LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $30,000. Aquatic Capital Management LLC boosted its holdings in AxoGen by 287.8% in the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares in the last quarter. Arax Advisory Partners boosted its holdings in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in AxoGen in the fourth quarter valued at approximately $36,000. Finally, Kestra Advisory Services LLC purchased a new position in AxoGen in the fourth quarter valued at approximately $39,000. 80.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Kathy Johnson Weiler sold 14,150 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the transaction, the executive vice president directly owned 50,135 shares of the company’s stock, valued at approximately $2,373,390.90. This trade represents a 57.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 95,003 shares of company stock valued at $4,482,997. Corporate insiders own 2.44% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on AXGN. Wells Fargo & Company boosted their price objective on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Canaccord Genuity Group increased their target price on shares of AxoGen from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Jefferies Financial Group reissued a “buy” rating and issued a $55.00 price target on shares of AxoGen in a research report on Wednesday, July 29th. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research note on Friday, May 29th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $48.00 target price on shares of AxoGen in a research report on Wednesday, April 29th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

AxoGen Stock Up 8.5%

AxoGen stock opened at $50.40 on Friday. The stock has a 50 day moving average of $44.11 and a two-hundred day moving average of $38.96. AxoGen, Inc. has a twelve month low of $13.64 and a twelve month high of $51.06. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -74.12 and a beta of 1.11. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The business had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. As a group, research analysts expect that AxoGen, Inc. will post -0.45 earnings per share for the current year.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.